SCHEMBL23218279

SCHEMBL23218279

CCOC(=O)Cc1ccccc1OCc1cccc2oc(-c3cccc(CN)c3OC)cc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFD P00746 2/20 0.41
DPP4 P27487 2/20 0.39
ALOX5 P09917 1/20 0.38
ALDH1A1 P00352 6/20 0.38
HPGD P15428 6/20 0.38
TSHR P16473 3/20 0.38
CYP3A4 P08684 3/20 0.38
CYP2C19 P33261 3/20 0.38
MAPT P10636 3/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
CYP1A2 P05177 2/20 0.38
CYP2C9 P11712 2/20 0.38
NPC1 O15118 1/20 0.38
GMNN O75496 1/20 0.38
RAF1 P04049 1/20 0.38
TP53 P04637 1/20 0.38
CYP2D6 P10635 1/20 0.38
PKM P14618 1/20 0.38
ALOX15 P16050 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29853086 1.00 CFD (0.41) CFDDPP4ALOX5ALDH1A1HPGD
SCHEMBL29852955 0.90 DPP4 (0.42) CFDDPP4ALOX5ALDH1A1HPGD
SCHEMBL23218076 0.90 DPP4 (0.42) CFDDPP4ALOX5ALDH1A1HPGD
SCHEMBL29592859 0.89 CFD (0.46) CFDALDH1A1HPGDTSHRCYP3A4
SCHEMBL23218510 0.89 CFD (0.46) CFDALDH1A1HPGDTSHRCYP3A4
SCHEMBL29340027 0.89 ALDH1A1 (0.40) CFDALDH1A1HPGDTSHRCYP3A4
SCHEMBL23218624 0.87 ALDH1A1 (0.38) CFDALOX5ALDH1A1HPGDTSHR
SCHEMBL29852653 0.87 ALDH1A1 (0.38) CFDALOX5ALDH1A1HPGDTSHR
SCHEMBL23218363 0.83 TBXAS1 (0.37) CFDDPP4ALOX5ALDH1A1HPGD
SCHEMBL29852490 0.83 TBXAS1 (0.37) CFDDPP4ALOX5ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
US-20240239752-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-07-18 US disclosed
US-20240239752-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-07-18 US disclosed
US-20240239752-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-07-18 US disclosed
CN-117120419-A KLK5 bicyclic heteroaromatic inhibitors 拜奥克里斯特制药公司 2023-11-24 CN disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239752-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 KLK5, KLK1, KLKB1 CFD 3529/4885DPP4 544/4885ALOX5 1408/4885
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB CFD 1/4885DPP4 1386/4885ALOX5 317/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CFD 1/4885DPP4 1004/4885ALOX5 260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.